MedTrace Logo

MRI- Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer

NCT03996005 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-01-08

Study results available
· View outcomes & findings →

Summary

Primary purpose :

Evaluation of the efficiency and safety of an alternative global prostate treatment in localized prostate cancer.

Primary Objective:

Absence of clinically significant cancer (CSC) on control biopsy at 1-year follow-up.

Secondary Objectives:

1. Biochemical response
2. Presence of any CSC on biopsy at 1- and 2-year follow-up
3. Radical treatment free survival
4. Adverse events, clinical tolerance
5. Urinary continence
6. Erectile function
7. Quality of life

Conditions

Interventions

PROCEDURE

Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue

Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue

Sponsors & Collaborators

  • University Hospital, Strasbourg, France

    lead OTHER

Principal Investigators

  • Thibault TRICARD, MD · University Hospital, Strasbourg, France

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-24
Primary Completion
2023-07-25
Completion
2023-07-25

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03996005 on ClinicalTrials.gov